Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.69 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lofentanil SCHEMBL1952939 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| Lofentanil SCHEMBL26429 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| Lofentanil SCHEMBL11565496 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| Lofentanil SCHEMBL30637157 | 0.98 | OPRM1 (0.96) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| Lofentanil SCHEMBL123003 | 0.98 | OPRM1 (0.96) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| Lofentanil SCHEMBL29361613 | 0.98 | OPRM1 (0.96) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| SCHEMBL11567176 | 0.91 | OPRM1 (0.83) | OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL11567179 | 0.91 | OPRM1 (0.83) | OPRM1OPRK1OPRL1OPRD1 | |
| Lofentanil SCHEMBL18730637 | 0.90 | OPRM1 (0.81) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| SCHEMBL11565454 | 0.90 | OPRM1 (0.82) | OPRM1OPRK1OPRL1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12529695-B2 | Fentanyl analogue detection methods and kits thereof | VERITEQUE USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20220390439-A1 | FENTANYL ANALOGUE DETECTION METHODS AND KITS THEREOF | VERITEQUE USA, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20210093557-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | ADAPT PHARMA LTD (IE) | 2021-04-01 | — | — | US | disclosed |
| US-20200030229-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | Adapt Pharma Limited | 2020-01-30 | — | — | US | disclosed |
| US-20190015323-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | Adaph Pharma Limited | 2019-01-17 | — | — | US | disclosed |
| US-20170071851-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | INDIVIOR UK LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| US-20170071851-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | INDIVIOR UK LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-4179569-A | ANALGESIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071851-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885OPRL1 1/4885 |
| US-20210093557-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885OPRL1 1/4885 |
| US-12529695-B2 | Fentanyl analogue detection methods and kits thereof | CA13, CA2, CA12 | OPRM1 24/4885OPRK1 19/4885OPRL1 25/4885 |
| US-20190015323-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885OPRL1 1/4885 |
| US-20200030229-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885OPRL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.